We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Mobile Testing Platform Performs World's Fastest Multiplex PCR and RT-PCR Analysis

By LabMedica International staff writers
Posted on 29 Jun 2022
Print article
Image: Chronos Dx platform (Photo courtesy of BforCure)
Image: Chronos Dx platform (Photo courtesy of BforCure)

Polymerase Chain Reaction (PCR) is an enzymatic amplification technique that produces a large number of identical copies of a DNA or RNA fragment and visualizes it by fluorescence. This very fast, sensitive and sequence-specific technique is much more efficient than traditional culture-based diagnostic methods, which suffer from long delays in obtaining results (from several days to several weeks). This is currently the most relevant method for rapid detection of genetic sequences in a sample, for example those of bacteria or viruses causing infectious diseases. In addition to classical PCR, there are several other types of PCR such as RT-PCR (reverse transcription PCR), qPCR (quantitative PCR), dPCR (digital PCR) and ddPCR (droplet digital PCR). Now, a new techniques named hcPCR (high content PCR), combines the advantages of qPCR and dPCR, in order to detect a large number of targets per test (multiplexing) and obtain the maximum amount of information in record time.

The hcPCR technique has been developed at BforCure (Paris, France) with Chronos Dx, its mobile, easy-to-use PCR/RT-PCR testing tool that delivers in vitro diagnosis of many infectious diseases in less than 15 minutes. While real-time PCR or RT-PCR typically takes 35 minutes to one hour to detect genetic material, BforCure's Chronos Dx platform performs multiplex PCR and RT-PCR analysis in record time. With the company’s Bflash+ range of kits optimized for research purposes, it is even possible to obtain accurate test results in less than five minutes.

Chronos Dx is based on a combination of microfluidic and optical technologies, which allows for ultra-fast temperature changes in the reaction mixture, reduced PCR cycle times and the detection of multiple genetic targets present in a sample, all in a single test (multiplexing principle). Chronos Dx enables ultra-fast PCR tests to be performed on a wide range of infectious diseases (respiratory, digestive and sexually transmitted). The infectious disease PCR testing tool offers a reliable and rapid response to the needs of laboratories regarding the detection of microorganisms, whether in the medical, environmental or industrial fields. Mobile, easy to use and connected, the Chronos Dx platform can be directly used in delocalized "satellite laboratories", as close as possible to the needs of healthcare professionals. It allows medical laboratories to manage urgent samples by performing unit analyses of numerous contagious pathologies, in order to accelerate patient care.

Related Links:

Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
Automated Hematology Workstation
Infliximab Immunoassay
Portable Molecular Workstation
iPonatic III

Print article
IIR Middle East



view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.